Rakovina Therapeutics Inc (RKV) - Net Assets
Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has net assets worth CA$1.89 Million CAD (≈ $1.37 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$5.27 Million ≈ $3.81 Million USD) and total liabilities (CA$3.38 Million ≈ $2.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Rakovina Therapeutics Inc for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$1.89 Million |
| % of Total Assets | 35.84% |
| Annual Growth Rate | -20.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.75 |
Rakovina Therapeutics Inc - Net Assets Trend (2021–2024)
This chart illustrates how Rakovina Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Check how tangible is Rakovina Therapeutics Inc's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual net assets of Rakovina Therapeutics Inc from 2021 to 2024. For live valuation and market cap data, see RKV market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$4.30 Million ≈ $3.11 Million |
+17.46% |
| 2023-12-31 | CA$3.66 Million ≈ $2.65 Million |
-39.14% |
| 2022-12-31 | CA$6.01 Million ≈ $4.35 Million |
-29.62% |
| 2021-12-31 | CA$8.54 Million ≈ $6.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Rakovina Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 947677700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$19.30 Million | 448.88% |
| Total Equity | CA$4.30 Million | 100.00% |
Rakovina Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Rakovina Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gafisa S.A
SA:GFSA3
|
$1.68 Million |
|
CryptoStar Corp
V:CSTR
|
$1.69 Million |
|
Radaan Mediaworks India Limited
NSE:RADAAN
|
$1.69 Million |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
$1.69 Million |
|
Synthomer plc
LSE:SYNT
|
$1.68 Million |
|
abrdn European Logistics Income PLC
LSE:ASLI_old
|
$1.68 Million |
|
Linkers Industries Limited Class A Ordinary Shares
NASDAQ:LNKS
|
$1.68 Million |
|
OBERON URANIUM CORP.
F:G7I
|
$1.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rakovina Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,659,836 to 4,298,915, a change of 639,079 (17.5%).
- Net loss of 4,072,618 reduced equity.
- New share issuances of 4,920,000 increased equity.
- Other factors decreased equity by 208,303.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-4.07 Million | -94.74% |
| Share Issuances | CA$4.92 Million | +114.45% |
| Other Changes | CA$-208.30K | -4.85% |
| Total Change | CA$- | 17.46% |
Book Value vs Market Value Analysis
This analysis compares Rakovina Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.90x to 2.31x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CA$0.12 | CA$0.11 | x |
| 2022-12-31 | CA$0.86 | CA$0.11 | x |
| 2023-12-31 | CA$0.52 | CA$0.11 | x |
| 2024-12-31 | CA$0.05 | CA$0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rakovina Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.45x
- Recent ROE (-94.74%) is below the historical average (-69.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -64.62% | 0.00% | 0.00x | 1.01x | CA$-6.38 Million |
| 2022 | -46.41% | 0.00% | 0.00x | 1.02x | CA$-3.39 Million |
| 2023 | -71.39% | 0.00% | 0.00x | 1.41x | CA$-2.98 Million |
| 2024 | -94.74% | 0.00% | 0.00x | 1.45x | CA$-4.50 Million |
Industry Comparison
This section compares Rakovina Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $14,958,100
- Average return on equity (ROE) among peers: -37.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rakovina Therapeutics Inc (RKV) | CA$1.89 Million | -64.62% | 1.79x | $1.68 Million |
| Appili Therapeutics Inc (APLI) | $1.37 Million | -127.61% | 0.87x | $928.58K |
| Aptose Biosciences Inc (APS) | $-3.87 Million | 0.00% | 0.00x | $4.43 Million |
| Arch Biopartners Inc (ARCH) | $-563.41K | 0.00% | 0.00x | $29.89 Million |
| Biomind Labs Inc (BMND) | $-1.74 Million | 0.00% | 0.00x | $3.09 Million |
| Cybin Inc (CYBN) | $86.12 Million | -37.41% | 0.07x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $45.77 Million | -76.33% | 0.10x | $301.17 Million |
| Devonian Health Group Inc (GSD) | $12.74 Million | -25.03% | 0.50x | $15.09 Million |
| Helix BioPharma Corp. (HBP) | $4.92 Million | -31.91% | 0.19x | $78.46 Million |
| Hemostemix Inc (HEM) | $4.84 Million | -81.34% | 0.10x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $-4.46K | 0.00% | 0.00x | $1.13 Million |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more